Micro-cap gene therapy biotech Genprex prices $6 million IPO at $5 – Nasdaq
Nasdaq |
Micro-cap gene therapy biotech Genprex prices $6 million IPO at $5
Nasdaq Genprex, which is developing gene-based nanoparticle therapies to treat cancer, raised $6.4 million by offering 1.28 million shares at $5 per share. At that price, it commands a fully diluted IPO market cap of $75 million. Genprex plans to list on the … |
